Study Phase 3

A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects

  • 1 CSR Summary Not yet available
  • 1 NCT02269917 Not Available
  • 1 Primary Citation
  • Data Specification Not Available

Trial Information

Generic NameDarunavirProduct NamePREZISTA®Therapeutic AreaViral DiseasesEnrollment1149% Female18.00%%% White74.90%%
Product ClassAntiviral AgentSponsor Protocol NumberTMC114IFD3013 - WK48Data PartnerJohnson & JohnsonCondition StudiedHIV InfectionsMean/Median Age (Years)45.1

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.